Laurus Labs Ltd.

NSE: LAURUSLABS BSE: 540222 SECTOR: Pharmaceuticals & Drugs  149k   1k   467

341.80
-0.05 (-0.01%)
NSE: Today, 03:58 PM

Price Summary

Today's High

₹ 360

Today's Low

₹ 338

52 Week High

₹ 626.3

52 Week Low

₹ 337

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

18411.09 Cr.

Enterprise Value

19990.19 Cr.

No. of Shares

53.87 Cr.

P/E

23.32

P/B

4.86

Face Value

₹ 2

Div. Yield

0.59 %

Book Value (TTM)

₹  70.31

CASH

40.56 Cr.

DEBT

1619.66 Cr.

Promoter Holding

27.2 %

EPS (TTM)

₹  14.66

Sales Growth

-1.29%

ROE

24.65 %

ROCE

23.52%

Profit Growth

-21.55 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 29 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-1.29%
3 Year28.16%
5 Year20%

Profit Growth

1 Year-21.55%
3 Year99.13%
5 Year30.27%

ROE%

1 Year24.65%
3 Year27.56%
5 Year20.19%

ROCE %

1 Year23.52%
3 Year25.51%
5 Year19.68%

Debt/Equity

0.4793

Price to Cash Flow

22.37

Interest Cover Ratio

11.175359899854

CFO/PAT (5 Yr. Avg.)

1.12603290022276

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 27.2 0.04
Sep 2022 27.27 0.04
Jun 2022 27.27 0
Mar 2022 27.27 0
Dec 2021 27.27 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 99.13108806736% for the Past 3 years.
  • The company has shown a good revenue growth of 28.1586834872986% for the Past 3 years.
  • Company has been maintaining healthy ROE of 27.5639368575192% over the past 3 years.
  • Company has been maintaining healthy ROCE of 25.5076976583225% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 11.175359899854.
  • The Company has been maintaining an effective average operating margins of 23.0222285292718% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 53.2319924121202 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.12603290022276.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 7.50814895492753.

 Limitations

  • The company is trading at a high PE of 23.32.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
Net Sales 1176.2 932.58 1377.66 1495.25 1498.16
Total Expenditure 842.39 717.16 1004.75 1077.07 1072.12
Operating Profit 333.81 215.42 372.91 418.18 426.04
Other Income 4.5 7.19 2.29 2.93 4.1
Interest 20.59 20.94 29.29 27.5 37.91
Depreciation 59.33 59.72 60.94 66 75.55
Exceptional Items 0 0 0 0 0
Profit Before Tax 258.39 141.95 284.97 327.61 316.68
Tax 60.76 32.79 63.75 96 89.24
Profit After Tax 197.63 109.16 221.22 231.61 227.44
Adjusted EPS (Rs) 3.68 2.03 4.12 4.31 4.23

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 2026.84 2236.15 2797.34 4768.72 4707.04
Total Expenditure 1618.1 1884.69 2227.11 3258.85 3421.84
Operating Profit 408.75 351.46 570.23 1509.87 1285.2
Other Income 28.84 16.13 5.81 27.32 21.55
Interest 75.44 85.83 87.71 65.92 95.86
Depreciation 121.23 160.53 183.85 196.64 235.48
Exceptional Items 0 0 0 0 0
Profit Before Tax 240.91 121.22 304.48 1274.63 975.41
Tax 67.77 26.23 37.43 318.52 225.32
Net Profit 173.14 94.99 267.05 956.11 750.09
Adjusted EPS (Rs.) 3.27 1.79 5 17.82 13.96

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 106.03 106.44 106.91 107.32 107.47
Total Reserves 1407.27 1484.46 1708.89 2604.92 3280.74
Borrowings 141.66 258.66 165 382.64 549.67
Other N/C liabilities 36.15 40.43 52.08 178.68 236.55
Current liabilities 1268.02 1379.44 1636.72 2696.26 2899.57
Total Liabilities 2959.12 3269.43 3669.6 5969.82 7074
Assets
Net Block 1447.69 1598.99 1694.18 1818.04 2186.23
Capital WIP 163.18 107.15 66.53 324.17 755.03
Intangible WIP 0 0 0 0 0
Investments 51.74 58.32 58.32 318.89 361.72
Loans & Advances 27.87 24.03 39.42 91.84 69.82
Other N/C Assets 39.47 47.13 26.51 30.8 31.16
Current Assets 1229.16 1433.81 1784.64 3386.08 3670.04
Total Assets 2959.12 3269.43 3669.6 5969.82 7074
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 240.91 121.22 304.48 1274.63 975.41
Adjustment 208.04 242.18 288.19 240.43 322.36
Changes in Assets & Liabilities -18.48 -44.89 -208.54 -594.55 -308.46
Tax Paid -61.86 -25.34 -39.45 -226.06 -166.34
Operating Cash Flow 368.6 293.17 344.68 694.45 822.97
Investing Cash Flow -417.48 -256.58 -216.83 -899.68 -836.61
Financing Cash Flow 48.99 -36.93 -127.48 243.13 15.19
Net Cash Flow 0.12 -0.35 0.37 37.9 1.55

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 27.27 27.27 27.27 27.27 27.20
satyanarayana chava 16.58 - 16.58 15.83 15.83
satyanarayana cha... - 16.58 - - -
chava naga rani 6.55 6.55 6.55 5.89 5.89
nagarani chava - - - - -
naga rani chava - - - - -
srihari raju kali... - - - 4.90 4.90
kalidindi srihari ... - - - - -
chunduru venkata l... 2.58 - 2.51 - -
venkata lakshman r... - 2.51 - - -
chunduru venkatala... - - - 2.17 2.17
venkata ravi kumar... - 1.44 - - -
vantaram venkata r... 1.51 - - 1.51 1.51
venkata ravi kumar... - - 1.44 - -
krishnaveni vasire... 0.04 0.04 0.04 - -
hymavathi vantaram 0.04 0.04 0.04 - -
krishnaveni vasir... - - - 0.04 0.04
vijaya durga chint... - - - - -
vijaya durga chin... - - - 0.04 0.04
rama suryadevara 0.03 0.03 0.03 0.04 0.04
jayapadma chintal... - - - 0.04 0.04
vantaram hymavathi - - - 0.04 0.04
narasimha rao sury... 0.03 0.03 0.03 0.02 0.02
chava narasimha rao 0.02 0.02 0.02 - -
sekhar babu chund... 0.02 0.02 0.02 0.02 0.02
nagamani thokala 0.02 0.02 0.02 0.02 0.02
kamala kommana 0.02 0.02 0.02 0.02 0.02
chandra kanth cher... 0.01 - 0.01 - -
chandrakanth chere... - 0.01 - - -
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 72.73 72.73 72.73 72.73 72.80
bluewater investme... - - - 19.80 19.80
ambit capital priv... - - - - -
fil capital manage... - - - 11.54 11.54
amansa holdings pr... 5.04 4.80 3.84 - -
new world fund inc 1.68 2.02 4.17 - -
sbi magnum taxgain... - - - 4.30 4.19
smallcap world fun... 1.10 1.10 2.28 - -
kalidindi srihari ... 3.26 3.04 2.90 - -
anukar projects pr... 3.20 3.20 3.20 - -
kotak equity hybrid - - - - -
kotak mahindra bal... - - - 2.95 3.00
qualified institut... 1.11 1.42 - - -
vijaya lakshmi yel... - - - 2.75 2.09
nomura india inves... - - - 2.03 1.65
bnp paribas arbitr... - 1.02 - - -
government pension... - - - - -
max life insuranc... - - - - -
kotak debt hybrid - - - - -
societe generale -... - - - - -
yalavarthy vijaya ... - - - - -
goldman sachs indi... - - - 1.35 1.35
societe generale 1.13 1.23 - - -
akash bhanshali - - - - -
max life insuranc... - - - - -
aadi financial adv... - - - - -
the nomura trust a... - - - 1.07 1.07
morgan stanley inv... - - - 1.03 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Laurus Labs reports 31% rise in Q3 consolidated net profit 30 Jan 2023, 4:00PM Laurus Labs informs about certificate7 Jan 2023, 12:09PM Laurus Labs informs about closure of trading window31 Dec 2022, 10:03AM Laurus Labs informs about flash fire in manufacturing plant27 Dec 2022, 9:53AM Laurus Labs enters into share subscription agreement with Ethan Energy India25 Nov 2022, 10:07AM USFDA completes pre-approval inspection at Laurus Labs’ facility in Andhra Pradesh29 Oct 2022, 12:40PM Laurus Labs informs about company updates29 Oct 2022, 11:47AM Laurus Labs informs about press release21 Oct 2022, 4:39PM Laurus Labs informs about presentation 21 Oct 2022, 4:35PM Laurus Labs - Quaterly Results21 Oct 2022, 2:57PM Laurus Labs - Quaterly Results21 Oct 2022, 2:57PM Laurus Labs - Quaterly Results21 Oct 2022, 2:57PM Laurus Labs informs about disclosure 18 Aug 2022, 12:56PM Laurus Labs reports 5% rise in Q1 consolidated net profit28 Jul 2022, 3:44PM Laurus Labs informs about presentation 27 Jul 2022, 5:04PM Laurus Labs informs about press release27 Jul 2022, 4:55PM Laurus Labs - Quaterly Results27 Jul 2022, 2:46PM Laurus Labs - Quaterly Results27 Jul 2022, 2:46PM Laurus Labs - Quaterly Results27 Jul 2022, 2:46PM Laurus Labs informs about certificate8 Jul 2022, 11:50AM Laurus Labs informs about analyst meet20 Jun 2022, 12:09PM Laurus Labs informs about analyst meet investor meeting13 Jun 2022, 10:36AM Laurus Labs informs about certificate 2 Jun 2022, 4:57PM Laurus Labs informs about annual secretarial compliance report11 May 2022, 12:55PM Laurus Labs informs about disclosure28 Apr 2022, 5:23PM Laurus Labs informs about press release28 Apr 2022, 4:42PM Laurus Labs informs about investor presentation28 Apr 2022, 4:39PM Laurus Labs informs about interim dividend28 Apr 2022, 4:38PM Laurus Labs informs about book closure28 Apr 2022, 4:32PM Laurus Labs - Quaterly Results28 Apr 2022, 2:45PM Laurus Labs - Quaterly Results28 Apr 2022, 2:45PM Laurus Labs - Quaterly Results28 Apr 2022, 2:45PM Laurus Labs informs about investor presentation14 Mar 2022, 4:42PM Laurus Labs reports 43% fall in Q3 consolidated net profit27 Jan 2022, 5:56PM Laurus Labs informs about investors presentation27 Jan 2022, 4:53PM Laurus Labs informs about press release27 Jan 2022, 4:34PM Laurus Labs informs about press release21 Jan 2022, 9:53AM Laurus Labs signs agreement with MPP21 Jan 2022, 9:42AM Laurus Labs signs investment agreement with Immunoadoptive Cell Therapy19 Nov 2021, 3:41PM Laurus Labs informs about outcome of board meeting29 Oct 2021, 9:42AM Laurus Labs informs about conference call21 Oct 2021, 10:31AM Laurus Labs informs about board meeting20 Oct 2021, 2:20PM Laurus Labs informs about certificate11 Oct 2021, 3:55PM Laurus Labs informs about press release14 Sep 2021, 5:00PM Laurus Labs developing third-line HIV treatment for children14 Sep 2021, 2:40PM Laurus Labs informs about disclosures19 Jul 2021, 5:16PM Laurus Labs informs about press release2 Jul 2021, 2:33PM Laurus Labs gets license to manufacture, market 2-Deoxy-D-Glucose in India2 Jul 2021, 2:18PM Laurus Labs reports around 3-fold jump in Q4 consolidated net profit30 Apr 2021, 10:37AM Laurus Labs informs about investor presentation29 Apr 2021, 3:51PM

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Laurus Labs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 822.97 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Laurus Labs has a Debt to Equity ratio of 0.4793 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Laurus Labs , the EPS growth was -21.6568731444222 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Laurus Labs has OPM of 27.3037832693157 % which is a good sign for profitability.
     
  • ROE: Laurus Labs have a healthy ROE of 24.6480273264535 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Laurus Labs

X